

REMARKS

Further and favorable reconsideration is respectfully requested in view of the foregoing amendments and following remarks.

Claims 1-8 have been amended to replace the phrase “fused bicyclic pyrimidine derivative” with --compound--, and to delete the word “general”, in response to the Examiner’s suggestion in item (i) on page 2 of the Office Action. Claim 1 has been further amended to limit the ring according to the disclosure on page 19, line 15 of the specification, in response to the Examiner’s statement in item (ii) on page 2 of the Office Action. Claim 16 has been amended to recite a pharmaceutical composition comprising an effective amount of a compound of formula (1) according to claim 1, and a pharmaceutically acceptable adjuvant, in response to the Examiner’s suggestion in item (iii) on page 2 of the Office Action. Claim 12 has been amended to delete “preventing” and “such as”, in response to the Examiner’s statement in item (iv) on page 2 of the Office Action. Claim 17 has been added to the application to recite the subject matter deleted from claim 12. Claims 10, 11 and 13-15 have been cancelled.

The rejection of claims 1-16 under 35 U.S.C. § 112, second paragraph, is rendered moot in light of the above-discussed amendments.


The rejection of claims 10 and 11 under 35 U.S.C. § 112, first paragraph, is rendered moot due to the cancellation of these claims.

The rejection of claims 12-15 under 35 U.S.C. § 112, first paragraph, is rendered moot in light of the above-discussed amendments.

Therefore, in view of the foregoing amendments and remarks, it is submitted that each of the grounds of rejection set forth by the Examiner has been overcome, and that the application is in condition for allowance. Such allowance is solicited.

Respectfully submitted,

Shigeki SETO et al.

By: 
Amy E. Pulliam
Registration No. 55,965
Agent for Applicants

AEP/nrj
Washington, D.C. 20006-1021
Telephone (202) 721-8200
Facsimile (202) 721-8250
October 11, 2005